BS_3T6X4BPC
DNET
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- DNET
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- DNET
- age_years
- 17.808
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.499
- MYOGENESIS+0.366
- PANCREAS_BETA_CELLS+0.349
- APICAL_SURFACE+0.269
- SPERMATOGENESIS+0.231
- ESTROGEN_RESPONSE_LATE+0.214
- APICAL_JUNCTION+0.163
- HEDGEHOG_SIGNALING+0.155
- ESTROGEN_RESPONSE_EARLY+0.123
- ANGIOGENESIS+0.118
Top 10 suppressed
- MYC_TARGETS_V1-0.656
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.585
- PROTEIN_SECRETION-0.577
- DNA_REPAIR-0.557
- UNFOLDED_PROTEIN_RESPONSE-0.553
- MTORC1_SIGNALING-0.529
- G2M_CHECKPOINT-0.523
- OXIDATIVE_PHOSPHORYLATION-0.501
- INTERFERON_ALPHA_RESPONSE-0.477
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_C7N3J4NW | high-grade glioma | — | 0.978 |
| 2 | BS_CZ82ANWP | DNET | — | 0.968 |
| 3 | SRR6013488 | — | cohortA1 | 0.965 |
| 4 | BS_SM8VQFPD | DNET | — | 0.965 |
| 5 | BS_KPT2WPHW | Ganglioglioma | — | 0.963 |
| 6 | SRR1418127 | GTEX | — | 0.958 |
| 7 | SRR1361674 | GTEX | — | 0.953 |
| 8 | BS_9F09XV62 | low-grade glioma | — | 0.952 |
| 9 | SRR1331751 | GTEX | — | 0.952 |
| 10 | BS_CQSAJ7BF | DNET | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.499 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.366 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.349 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.269 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.231 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.214 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.163 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.155 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.123 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.118 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.103 | Inavolisib | — uncovered |
| COAGULATION | 0.063 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.044 | Inavolisib | — uncovered |